small molecule glp-1 agonist In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with Current Insights, Advantages and Challenges
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17























)



